According to Citi, the delay in the launch of Sun Pharma’s alopecia areata drug, Leqselvi, could impact its near-term earnings by 3-6% of EPS and may also affect competitive positioning, as rival drugs will have longer-term clinical data by the time Sun’s product reaches the market.
